|Year : 2019 | Volume
| Issue : 4 | Page : 981-982
Early addition of rituximab in the management of myositis associated with systemic lupus erythematosus
Mervat E Behiry, Ahmed Shaker, Kyrillus Shohdy, Fadi Nagy
Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, Egypt
|Date of Submission||06-Oct-2018|
|Date of Acceptance||07-Aug-2018|
|Date of Web Publication||18-Aug-2020|
BSc Ahmed Shaker
Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, 12613
Source of Support: None, Conflict of Interest: None
Targeting B-cell in systemic lupus erythematosus (SLE) seems to be a promising approach. Although rituximab failed to show efficacy in refractory SLE in clinical trial setting, real-world experience still shows some efficacy in certain situations. A 20-year-old woman was diagnosed with SLE with coexistent myositis. The patient’s muscular condition did not improve on corticosteroids, addition of rituximab could achieve complete response. Introducing rituximab early for the nonrenal manifestations of SLE merits further investigation.
Keywords: myositis, rituximab, systemic lupus erythematosus
|How to cite this article:|
Behiry ME, Shaker A, Shohdy K, Nagy F. Early addition of rituximab in the management of myositis associated with systemic lupus erythematosus. Egypt J Intern Med 2019;31:981-2
|How to cite this URL:|
Behiry ME, Shaker A, Shohdy K, Nagy F. Early addition of rituximab in the management of myositis associated with systemic lupus erythematosus. Egypt J Intern Med [serial online] 2019 [cited 2020 Oct 1];31:981-2. Available from: http://www.esim.eg.net/text.asp?2019/31/4/981/292255
| Introduction|| |
Systemic lupus erythematosus (SLE) is an auto-inflammatory disorder with a myriad of systemic affections and manifestations. B-cells play an important role in the pathogenesis of SLE. This pushes investigation of anti-B-cell antibody therapies such as rituximab (anti-CD20) in the refractory cases of SLE. Several case series and off-label experiences showed promising efficacy of rituximab. However, the three prospective clinical trials of rituximab in patients with refractory SLE failed to meet their primary endpoints. Currently there is only one drug, belimumab, that targets B-cells that holds approval from US FDA in such setting based on three positive clinical trials . This heterogenous results suggest the potential role of rituximab for a selected population of SLE patients.
| Case presentation|| |
A 20-year-old woman presented to our clinic with fever of 1-month duration that was associated with arthralgia involving both the knees, ankles, elbows, and wrists. She also had malar rash and symmetric weakness of both extremities. She reported dyspnea on mild exertion. She denied hair loss, Raynaud’s phenomenon, or any other musculoskeletal manifestations. Physical examination showed proximal muscle wasting of both upper and lower limbs. Lab workup showed microcytic hypochromic anemia with leukopenia, Erythrocyte sidemination rate (ESR) of 123, and C-reactive protein (CRP) of 120 mg/l (normal<5). Lactate dehydrogenase (LDH) was elevated to 462 U/l (NL<247) with a creatine phosphokinase value of 282 (NL: 60–170). Her serology was positive for Anti nuclear antibodies (ANA) and anti-dsDNA. C3 and C4 were consumed. electromyography (EMG) showed excessive spontaneous activity, polyphasic potentials of short duration and low amplitude confirming diffuse myositis of the proximal and distal muscles of both upper and lower limbs. Screening for renal and other system affections was unremarkable. Diagnosis of SLE was made and the patients started corticosteroids and showed improvement of fever and hematologic indices. In view of persistent severe muscle weakness, she received rituximab 1 g every 2 weeks. After two doses, her muscular condition was completely improved. Muscle enzymes and EMG were normal. Then she was kept on the standard treatment.
| Discussion|| |
Several studies either retrospective or prospective randomized trials have investigated the efficacy and safety of rituximab for refractory SLE patients. Not all SLE manifestations respond the same to rituximab. Proliferative nephritis and central nervous system (CNS) affection were among the most common responding disease activities. Muscular affection is a pertinent feature of SLE and is highly variable across studies (range: 2.6–16%) . It is important in this regard to differentiate between myalgia, which is a common symptom, and true myositis; the latter has to satisfy the following criteria: (a) persistent muscle weakness in the proximal or distal extremities, (b) increased levels of creatine phosphokinase, and (c) abnormal EMG. Overlap syndrome should be carefully excluded. One cross-sectional study  on 1701 lupus patients could identify 44 (2.6%) patients with SLE-associated myositis. Myositis in those SLE patients tend to present with weakness rather diffuse pain without dysphagia or respiratory muscles affection. In studies of rituximab in refractory SLE, few reports of SLE-associated myositis were included. For instance, one case series of 107 SLE patients, only one patient of the three with muscular affection achieved organ-specific response . Data on muscular affection response is sparse due to the infrequency of such events and poor characterization of such manifestation ([Table 1]). It is of utmost importance to distinguish true inflammatory myositis from other muscle-related conditions in SLE. Myositis-associated SLE in our patient was diagnosed based on clinical examination and EMG. EMG is still the most accurate practical way to diagnose true myositis from myalgia and fatigue . Biopsy is not required in most occasions. Introducing rituximab in early phase may contribute to the marked response in our case. Proper selection and tailoring options might improve the response rate of SLE patients with nonrenal manifestations to the commonly available anti-B-cell therapies such as rituximab.
|Table 1 Studies reporting response of myositis-associated systemic lupus erythematosus to rituximab|
Click here to view
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Oon S, Huq M, Godfrey T, Nikpour M. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. Semin Arthritis Rheum 2018; 48:221–239.
Cobo-Ibáñez T, Loza-Santamaría E, Pego-Reigosa JM, Marqués AO, Rúa-Figueroa Í, Fernández-Nebro A et al.
Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum 2015; 44:175–185.
Liang Y, Leng RX, Pan HF, Ye DQ. Associated variables of myositis in systemic lupus erythematosus: a cross-sectional study. Med Sci Monit 2017; 23:2543–2549.
Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L et al.
Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol 2009; 28:468–476.
Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T et al.
A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007; 17:191–197.
Hui M, Andres M, Latied K, Courtney P. Small muscle myositis in a patient with systemic lupus erythematosus successfully treated with rituximab. Lupus 2011; 20:1340–1341.
Bang SY, Lee CK, Kang YM, Kim HA, Suh CH, Chung WT et al.
Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus. Autoimmune Dis 2012; 2012:1–6.
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344–347.